Is AZN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,931 people get AZN articles and Market Currents by email alert.

Get email alerts on AZN »

HEADLINES:

Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013

Business Wire (Tue, 9:25AM)
AstraZeneca: A Dividend Payer With An Attractive Growth Prospect
Fund Gurus • Mon, May 20
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
What To Buy And Sell In Your High-Yield Portfolio
Monty Spivak • Tue, May 14 • 22 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Tue, May 14 • 93 Comments
Assessing Your Asthma is Key to Taking Control

PR Newswire (May 13, 2013)
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
6 Superstars For Your Biotech Portfolio: John McCamant
Life Sciences Report • Fri, May 10 • 1 Comment
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 61 Comments
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
PropThink • Wed, May 8 • 4 Comments
What Is Due Diligence For (Exponential) Dividend Growth Stocks?
Roger F. Goodrich • Mon, May 6 • 32 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
AstraZeneca's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, Apr 26
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Thu, Apr 25 • 46 Comments
Will The Big Pharmaceuticals Fall Off A Patent Cliff?
Fund Gurus • Wed, Apr 24 • 2 Comments
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential
Trade In Mexico • Wed, Apr 24 • 26 Comments
Array's Up-Coming Value Enhancing Catalysts
Veziris Ventures • Wed, Apr 17 • 2 Comments
Pfizer's New Breast Cancer Drug Could Be A Game Changer
StockBaller • Mon, Apr 15 • 4 Comments
54 Dividend Challengers Yielding 100% More Than 10-Year Treasuries
David Van Knapp • Thu, Apr 11 • 9 Comments

To learn more about Seeking Alpha Pro, click here.

AstraZeneca: A Dividend Payer With An Attractive Growth Prospect
Fund Gurus • Mon, May 20
AstraZeneca's Move To Hot, Happening Cambridge
Derek Lowe • Wed, Apr 3 • 2 Comments
AstraZeneca's Strategy To Return To Growth Will Take Time
Steven Dotsch • Tue, Apr 2 • 5 Comments
No Quick Fixes, But Astra's Soriot Can Still Be Bold
EP Vantage • Tue, Mar 19 • 1 Comment
Why AstraZeneca Will Disappoint In 2013
Bio Matt • Sun, Mar 17 • 7 Comments
Why AstraZeneca Is Worth Paying Close Attention To
Valuentum • Tue, Dec 4, 2012 • 4 Comments
Forxiga For Type 2 Diabetes Is A Potential Blockbuster - Buy AstraZeneca
Pharma Intelligence • Fri, Nov 16, 2012 • 5 Comments
Avoid This Big Pharma As New Regulations Churn
Stock Croc • Mon, Oct 29, 2012 • 1 Comment
AstraZeneca May Not Be Immune To Patent Cliff But Dividend Is Solid
Valuentum • Sun, Oct 28, 2012 • 1 Comment
With AstraZeneca's Results Down Is Its Dividend Safe?
Steven Dotsch • Thu, Oct 25, 2012
Competition Creates Uncertainty For AstraZeneca
ValueMax • Mon, Oct 15, 2012
Sell AstraZeneca: Share Buyback Suspension Comes As Further Bad News
Qineqt • Wed, Oct 3, 2012
AstraZeneca Will Rise Again
Ron Sommer • Tue, Oct 2, 2012 • 1 Comment
AstraZeneca Suspends The Buyback: Let The M&A Speculation Commence
Stephen Simpson • Mon, Oct 1, 2012 • 15 Comments
AstraZeneca: New Bonds Sign Of Times
Charles Margolis • Mon, Sep 17, 2012 • 5 Comments
AstraZeneca: Will New Drugs And CEO Reward Investors?
Cris Frangold • Tue, Sep 11, 2012 • 2 Comments
Buy AstraZeneca For 6% Dividend Yield; No Capital Appreciation Warranted
Qineqt • Wed, Sep 5, 2012 • 11 Comments
AstraZeneca: Don't Sell This Stock
Mel Daris • Mon, Aug 27, 2012 • 9 Comments
AstraZeneca In Strong Position With Brilinta
Cris Frangold • Mon, Aug 27, 2012 • 1 Comment
It's Time To Be Optimistic About AstraZeneca
Pharma Intelligence • Wed, Aug 22, 2012 • 13 Comments

Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
What To Buy And Sell In Your High-Yield Portfolio
Monty Spivak • Tue, May 14 • 22 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Tue, May 14 • 93 Comments
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
6 Superstars For Your Biotech Portfolio: John McCamant
Life Sciences Report • Fri, May 10 • 1 Comment
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 61 Comments
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
PropThink • Wed, May 8 • 4 Comments
What Is Due Diligence For (Exponential) Dividend Growth Stocks?
Roger F. Goodrich • Mon, May 6 • 32 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Thu, Apr 25 • 46 Comments
Will The Big Pharmaceuticals Fall Off A Patent Cliff?
Fund Gurus • Wed, Apr 24 • 2 Comments
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential
Trade In Mexico • Wed, Apr 24 • 26 Comments
Array's Up-Coming Value Enhancing Catalysts
Veziris Ventures • Wed, Apr 17 • 2 Comments
Pfizer's New Breast Cancer Drug Could Be A Game Changer
StockBaller • Mon, Apr 15 • 4 Comments
54 Dividend Challengers Yielding 100% More Than 10-Year Treasuries
David Van Knapp • Thu, Apr 11 • 9 Comments
9 NYSE International 100 Dogs Hunt 6.5% To 24.7% Net Gains In April
Fredrik Arnold • Thu, Apr 11 • 8 Comments
3 Healthcare Stocks With Greater Than 4% Dividend Yields To Inject Life Into Your Portfolio
Black Coral Research • Wed, Apr 10 • 5 Comments
3 Dividend Stocks That Will Never Disappoint You
Fusion Research • Wed, Apr 10 • 5 Comments
Prolor Biotech: Unlimited Upside?
Daniel Lauchheimer • Tue, Apr 9 • 12 Comments

AstraZeneca's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, Apr 26
AstraZeneca's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Jan 31
AstraZeneca PLC Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
AstraZeneca PLC Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 26, 2012
AstraZeneca Management Discusses Q3 2010 Results – Earnings Call Transcript
Sun, Oct 31, 2010
AstraZeneca PLC Q2 2010 Earnings Call Transcript
Thu, Jul 29, 2010
AstraZeneca Q3 2007 Earnings Call Transcript
Thu, Nov 1, 2007
AstraZeneca Q2 2007 Earnings Call Transcript
Thu, Jul 26, 2007
MedImmune Q4 2006 Earnings Call Transcript
Wed, Feb 7, 2007
MedImmune Q3 2006 Earnings Call Transcript
Thu, Oct 26, 2006
MedImmune, Inc. Q2 2006 Earnings Conference Call Transcript (MEDI)
Thu, Jul 20, 2006
MedImmune, Inc. Q1 2006 Earnings Conference Call Transcript (MEDI)
Thu, Apr 20, 2006
Medimmune Q4 2005 Earnings Conference Call Transcript (MEDI)
Mon, Feb 6, 2006
Full Transcript of Medimmune’s 3Q05 Conference Call - Q&A (MEDI)
Wed, Nov 9, 2005
Full Transcript of Medimmune’s 3Q05 Conference Call - Prepared Remarks (MEDI)
Wed, Nov 9, 2005

Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013

Business Wire (Tue, 9:25AM)
Assessing Your Asthma is Key to Taking Control

PR Newswire (May 13, 2013)
Stocks End Off Highs, but S&P, Nasdaq Log Gains for 5th Day

at CNBC.com (Apr 25, 2013)
Europe Markets: Europe stocks rise as U.K. avoids recession

at MarketWatch.com (Apr 25, 2013)
London Markets: U.K. stocks rise as GDP data beat views

at MarketWatch.com (Apr 25, 2013)
Europe Closes Up on Upbeat UK GDP

at CNBC.com (Apr 25, 2013)
Futures Edge Higher on Earnings, Jobless Claims; 3M Slumps

at CNBC.com (Apr 25, 2013)
New Research Approach Tailors Drugs to Patients

at Fox Business (Apr 22, 2013)
A Make-or-Break Week Ahead for the Stock Market

at CNBC.com (Apr 20, 2013)
At a Loss ... 'Call Me, Faber' ... Rat-Sized Snails Attack!

at CNBC.com (Apr 19, 2013)
London Markets: Miners rebound in London; pharma, oil firms off

at MarketWatch.com (Apr 16, 2013)
London Markets: M&S leads FTSE 100 to fourth day of gains

at MarketWatch.com (Apr 11, 2013)
AstraZeneca's Arthritis Pill Disappoints in Late-Stage Trial

at Fox Business (Apr 5, 2013)
Early Movers: CAG, TSLA, VZ & More

at CNBC.com (Apr 3, 2013)
London Markets: Vodafone breakup talk boosts U.K. stocks

at MarketWatch.com (Apr 2, 2013)
Early Movers: Insurers, NDAQ, AAPL & More

at CNBC.com (Apr 2, 2013)
Early Movers: DG, APOL, SFD & More

at CNBC.com (Mar 25, 2013)
London Markets: U.K. stocks break losing streak; BP, AZN rise

at MarketWatch.com (Mar 22, 2013)
London Markets: U.K. stocks drop for fifth day; PMIs, Cyprus weigh

at MarketWatch.com (Mar 21, 2013)
AstraZeneca to Cut 5,050 Jobs by 2016

at Fox Business (Mar 21, 2013)

AZN vs. ETF Alternatives

Company Description

Currently, there's no company description for AZN.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United Kingdom

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 11:23 AM Impax Laboratories (IPXL -1.2%) says its Generic Division, Global Pharmaceuticals, has begun shipping its generic drug Zomig, which is used for the treatment of migraines in adults, as part of a licensing and distribution agreement with AstraZeneca (AZN). Comment! [Healthcare, Global & FX]
Monday, May 13, 5:09 PM Shares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale. Comment! [Healthcare, On the Move, M&A]
Wednesday, May 8, 11:35 AM Pozen (POZN -8.8%) falls after Q1 results miss estimates. The company says AstraZeneca (AZN), —which commercializes the osteoarthritis drug on which POZN receives royalties — plans to cease promotion of VIMOVO in the U.S. and Europe (ex-Spain and Portugal), although the product will still be available. Promotions will only continue in countries which account for 47% of Q1 sales. POZN says it is "unsure of the impact" the strategy change will have on future financial performance, but it is worth noting POZN derives all of its revenue from VIMOVO royalties. (PR) Comment! [Healthcare, On the Move, Earnings]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 7:52 AM Isis Pharmaceuticals (ISIS) initiates Phase 1b/2a clinical study — via licensing partner AstraZeneca (AZN) — of its antisense drug ISIS-STATRx in HCC patients. The effort is part of a broader initiative to study the drug in a number of different cancers. For more on ISIS' antisense technology, see SA contributor Jane Edmondson's recent writeup. (PR) Comment! [Healthcare]
Thursday, April 25, 5:52 AM AstraZeneca (AZN -1.4%) has received a subpoena from the U.S. Attorney's Office in Boston about production standards at the company's plant in Macclesfield in northern England. The facility is AstraZeneca's second largest manufacturing site and is used to produce its Zoladex line for prostate and breast cancers. (Q1 earnings) Comment! [Healthcare]
Thursday, April 25, 3:42 AM AstraZeneca (AZN): Q1 pretax profit -36% to $1.3B vs consensus of $1.75B, hurt by loss of patent protection for key products. Revenue -13% to $6.39B vs $6.53B. Adjusted EPS -25% to $1.41. For 2013, reiterates that it expects mid-to-high single digit decline in revenue. Sales breakdown: Seroquel (schizophrenia) -60.6% to $449M, Crestor (cholesterol) -12% to $1.32B, Symbicort +14.3% to $826M (asthma). Shares -1.2% in London. (PR) 1 Comment [Earnings, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Monday, April 22, 12:51 PM AstraZeneca (AZN +0.5%) is the latest major pharmaceutical company to license Bind Therapeutics' technology, agreeing to pay almost $200M in upfront and other payments - as well as royalties on any sales - for the rights to use the privately held company's nanotechnology drug delivery system. AstraZeneca intends to use Bind's particles, called Accurins, to develop cancer drugs that will selectively target tumor cells rather than healthy tissue. (PR) Comment! [Healthcare]
Thursday, April 18, 8:17 AM Theravance (THRX) looks poised for a strong session after an FDA advisory panel recommends approval of a once-daily COPD inhaled treatment option (Breo Ellipta) the company is developing with GlaxoSmithKline (GSK). Some color on the story: 1) the drug will be called "Relvar" in the U.S. 2) Annual sales should come in at ~$337M next year. 3) Treatment may be used in conjunction with GSK's $8B per year Advair. 4) Relvar will compete with AstraZeneca's Symbicort which had sales of $3.19B in 2012. THRX shares +16% premarket. 1 Comment [Healthcare, On the Move]
Monday, April 8, 12:07 PM S&P has cut AstraZeneca's (AZN +0.1%) credit outlook to negative as the company's plan to arrest falling revenues failed to impress. According to S&P, the loss of patent protection on key products will erode the company's top line by 9% in 2013, which could in turn cause AZN's funds from operations to net debt ratio to fall below the minimum level for AA-. Comment! [Healthcare]
Friday, April 5, 8:58 AM Rigel Pharmaceuticals (RIGL) plummets before the bell after adverse side effects were observed in a late-stage clinical trial of AstraZeneca's (AZN) rheumatoid arthritis drug fostamatinib. It also appears the drug may be inferior to AbbVie's Humira in terms of efficacy. The drug is licensed from Rigel whose shares are -35% premarket on heavy volume. Comment! [Healthcare, On the Move]
Friday, April 5, 3:38 AM AstraZeneca's (AZN) rheumatoid arthritis pill Fostamatinib met only one of its two main targets in a Phase III study in what is a further blow to the company as it seeks to overcome its patent cliff. While Fostamatinib brought about improvement in a test assessing signs and symptoms of the disease, the drug failed to do so as measured by X-ray. Still, expectations were low given disappointing results in earlier trials. (PR) Comment! [Healthcare]
Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
Wednesday, April 3, 7:55 AM AstraZeneca (AZN) gets a bit of respite Wednesday as a New Jersey court grants a temporary block on sales of Actavis' (ACT) generic version of asthma treatment Pulmicort Repsules. The court order lasts only until April 12, but it should buy AZN time to appeal an unfavorable ruling on its patent handed down earlier in the week. Comment! [Healthcare]

MSF INVESTMENTS
Housing improving, inventory all paid for, and low guidance = $SHLD numbers may be much better than expected. Lahiem $HD, $LOW, $AZN, $JCP,
Wed, 7:38 AM
Reply (2)

• !Report Abuse
View all 2 replies
MSF INVESTMENTS: Hurricane Sandy numbers kicking in.
Wed, 7:39 AM
• !Report Abuse
MSF INVESTMENTS: Squeeze time.
Wed, 9:46 AM
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
$AZN $SJR and $BBL are the highest yielding foreign dividend growth stocks - http://stks.co/pDU6 - 20 stocks with 2.86% Yield - $ACN $NVO
Mon, 3:34 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$FTE $SKM and $AZN are the cheapest foreign large caps with low beta ratios - http://stks.co/eUPq - 19 shares with 5.31% average yield
May 15, 7:53 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MSF INVESTMENTS
The new data subsidiary will be paying $SHLD rent for the buildings as well as revenue from the business.$WMT $GS $JCP $AN $AZN Lahiem
May 12, 7:22 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MSF INVESTMENTS
Sears "The Cash Cow" Holdings' data center venture is considered to be a gold mine. $SHLD $HD,$AMZ $AZN $WMT $BBY
May 11, 7:05 PM
Reply (2)

• !Report Abuse
View all 2 replies
MSF INVESTMENTS: ......and they said it was worthless real estate.
May 11, 7:06 PM
• !Report Abuse
MSF INVESTMENTS: Eddie Lampert will make gold out of mud.
May 11, 7:06 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
Sears "The Cash Cow" Holdings will be bigger, better and replace Amazon. $SHLD, $JCP, $HD, $AMZN, $AN, $AZN, $BBY,$WMT Lahiem
May 4, 4:30 PM
Reply (7)

• !Report Abuse
View all 7 replies
Energysystems: Recently was shopping for a ratcheting pipe cutter, ended up with a Craftsman, with free shipping. Can't knock it.
May 4, 7:20 PM
• !Report Abuse
MSF INVESTMENTS: All part of Lampert's plan.
May 4, 7:49 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
$SHLD is turning it's retail into an $AMZN with brands. $JCP, $HD, $BBY ,$AZN, $AN
May 4, 4:20 PM
Reply (4)

• !Report Abuse
View all 4 replies
MSF INVESTMENTS: Sears Holdings will replace Amazon.
May 4, 4:26 PM
• !Report Abuse
markrpat: bot my share of AMZN puts into close Friday. maybe shouldve waited a day, but nice to hear.
May 4, 7:29 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
Has anyone heard anything that Sears Auto has sold their locations to Autozone. $SHLD,$JCP,$AZN
Apr 30, 8:57 PM
Reply (3)

• !Report Abuse
View all 3 replies
Micah: Monetizing real-estate - http://goo.gl/V3hIC
May 1, 7:02 AM
• !Report Abuse
MSF INVESTMENTS: I heard it from someone..
May 1, 7:11 AM
• !Report Abuse
Add a reply...

140 characters

RSI Raistlin
$AZN calls in at 2.90 out at 3.30...was mobile for that one
Apr 26, 1:42 PM
Reply (1)

• !Report Abuse
View all 1 replies
RSI Raistlin: next entry eyed in the 253s
Apr 26, 1:42 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
KCD,IP llc. is also a debt free separate entity worth billions.$SHLD,$HD,$WMT,$JCP,$L ,$BBY, $AZN, $AN
Apr 25, 2:39 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

MSF INVESTMENTS
Housing improving, inventory all paid for, and low guidance = $SHLD numbers may be much better than expected. Lahiem $HD, $LOW, $AZN, $JCP,
Wed, 7:38 AM
Reply (2)

• !Report Abuse
View all 2 replies
MSF INVESTMENTS: Hurricane Sandy numbers kicking in.
Wed, 7:39 AM
• !Report Abuse
MSF INVESTMENTS: Squeeze time.
Wed, 9:46 AM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
Sears "The Cash Cow" Holdings' data center venture is considered to be a gold mine. $SHLD $HD,$AMZ $AZN $WMT $BBY
May 11, 7:05 PM
Reply (2)

• !Report Abuse
View all 2 replies
MSF INVESTMENTS: ......and they said it was worthless real estate.
May 11, 7:06 PM
• !Report Abuse
MSF INVESTMENTS: Eddie Lampert will make gold out of mud.
May 11, 7:06 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
Sears "The Cash Cow" Holdings will be bigger, better and replace Amazon. $SHLD, $JCP, $HD, $AMZN, $AN, $AZN, $BBY,$WMT Lahiem
May 4, 4:30 PM
Reply (7)

• !Report Abuse
View all 7 replies
Energysystems: Recently was shopping for a ratcheting pipe cutter, ended up with a Craftsman, with free shipping. Can't knock it.
May 4, 7:20 PM
• !Report Abuse
MSF INVESTMENTS: All part of Lampert's plan.
May 4, 7:49 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
$SHLD is turning it's retail into an $AMZN with brands. $JCP, $HD, $BBY ,$AZN, $AN
May 4, 4:20 PM
Reply (4)

• !Report Abuse
View all 4 replies
MSF INVESTMENTS: Sears Holdings will replace Amazon.
May 4, 4:26 PM
• !Report Abuse
markrpat: bot my share of AMZN puts into close Friday. maybe shouldve waited a day, but nice to hear.
May 4, 7:29 PM
• !Report Abuse
Add a reply...

140 characters

MSF INVESTMENTS
Has anyone heard anything that Sears Auto has sold their locations to Autozone. $SHLD,$JCP,$AZN
Apr 30, 8:57 PM
Reply (3)

• !Report Abuse
View all 3 replies
Micah: Monetizing real-estate - http://goo.gl/V3hIC
May 1, 7:02 AM
• !Report Abuse
MSF INVESTMENTS: I heard it from someone..
May 1, 7:11 AM
• !Report Abuse
Add a reply...

140 characters

RSI Raistlin
$AZN calls in at 2.90 out at 3.30...was mobile for that one
Apr 26, 1:42 PM
Reply (1)

• !Report Abuse
View all 1 replies
RSI Raistlin: next entry eyed in the 253s
Apr 26, 1:42 PM
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
$NMM $DX and $NRP are the best yielding Dividend Challengers - http://stks.co/cLQs - I like $APU $RAI and $AZN from the list
Feb 22, 4:33 AM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: I was unaware RAI paid that good a dividend. Good info Dividend Sheet Guy
Feb 22, 8:51 AM
• !Report Abuse
Ocean Man: I like APU and RAI too.
Feb 22, 11:22 AM
• !Report Abuse
Add a reply...

140 characters

MoneyWalksStocksTalk-2.0
$KOG ? Thoughts? $AZN - flu epidemic, they provide nasal vaccination which is popular , thoughts?
Jan 11, 11:59 AM
Reply (2)

• !Report Abuse
View all 2 replies
Hillbilly Stock Star: $KOG, $HK, $LPI just doing a little wildcatting, Long.
Jan 11, 12:32 PM
• !Report Abuse
Hillbilly Stock Star: $PNRA ....everybody here eating chicken soup.
Jan 11, 12:32 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them
8/28/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
10/25/12
• !Report Abuse
Add a reply...

140 characters

Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS
7/4/12
Reply (1)

• !Report Abuse
View all 1 replies
DaLatin: Not me.Like the dividend,but, IMHO JNJ is a Law firm who produces dangerous products for profit. Ya want to kill buy PM & get the divvy
7/4/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I have a new article out this morning at http://seekingalpha.com/a/ec5f $OMPI $AVP $AGN $AZN $RDEA
6/19/12
Reply (11)

• !Report Abuse
View all 11 replies
onehardroll: Does anyone know why there's a big short sell on ARNA?
6/19/12
• !Report Abuse
Studog: Loved SGYP today as well! Almost sold it this morning and now I am glad that I didn't. GLTA
6/19/12
• !Report Abuse
Add a reply...

140 characters

mitrado
Got 50 shares of $SDRL today. Waiting for $AZN & $JNJ to drop just a little bit more to add them to my good dividend portfolio.
5/29/12
Reply (8)

• !Report Abuse
View all 8 replies
mitrado: $SDRL keeps falling. As soon as I buy a stock, chances are it collapses over the following days. When I don't buy, I see them run away. :-/
6/1/12
• !Report Abuse
Energysystems: haha that usually happens to me too. If I don't pull the trigger I regret it, and if I do, I regret it.
6/1/12
• !Report Abuse
Add a reply...

140 characters

Windsun33
Is AZN undervalued or a value trap?
5/24/12
Reply (2)

• !Report Abuse
View all 2 replies
mitrado: I almost got in AZN last year. I gave up because the CEO didn't seem a good guy. Greedy and incompetent, in my opinion. But now he's gone :)
5/25/12
• !Report Abuse
mitrado: I was waiting to see if AZN would drop to $40... but by the looks of it, maybe I should wait for $38 now, eh?
5/25/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
15 High Yield Large Caps With Best Margin: http://bit.ly/p6T2oY + $NLY $SAN $TEF $WBK $SCCO $BBVA $SID $MO $AZN $NGG $CHT $RAI $HCP $STO $CM
9/22/11
Reply (1)

• !Report Abuse
View all 1 replies
golfitobob: PSEC has insider buying ! And, the DOW an S&P might go muck lower and then yields will be much higher. You say wait or buy now ? I wait! gb
9/22/11
• !Report Abuse
Add a reply...

140 characters

AZN AstraZeneca Group plc

AZN

AstraZeneca Group plc